You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

HER2-positive solid tumors

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

HER2-positive Advanced Solid Tumors Trial in Beijing, Guangzhou, Tianjin (SPH5030 tablets)

Recruiting
  • HER2-positive Advanced Solid Tumors
  • SPH5030 tablets
  • Beijing, Beijing, China
  • +2 more
Mar 10, 2022

HER2-Positive Solid Tumors Trial in Canada, United States (TAC01-HER2)

Recruiting
  • HER2-Positive Solid Tumors
  • TAC01-HER2
  • Chicago, Illinois
  • +4 more
Apr 27, 2022

HER-2 Gene Amplification, HER2-positive Gastric Cancer, HER2-positive Breast Cancer Trial in United States (chimeric antigen

Recruiting
  • HER-2 Gene Amplification
  • +4 more
  • chimeric antigen receptor (CAR) T cell therapy
  • Duarte, California
  • +6 more
Aug 10, 2022

HER2-positive Advanced Solid Tumors Trial in Shanghai (DP303c)

Recruiting
  • HER2-positive Advanced Solid Tumors
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Apr 10, 2023

HER-2 Positive Advanced Solid Tumors Trial (D3L-001)

Not yet recruiting
  • HER-2 Positive Advanced Solid Tumors
  • D3L-001
  • (no location specified)
Jul 20, 2023

HER2 Positive Advanced Solid Tumors Trial (HypoSti.CAR-HER2 T cells, Albumin-bound paclitaxel, Cyclophosphamide)

Not yet recruiting
  • HER2 Positive Advanced Solid Tumors
  • HypoSti.CAR-HER2 T cells
  • +2 more
  • (no location specified)
Jan 12, 2023

Her2-positive/Low-expression Urinary and Digestive Tract Tumors Trial in Beijing (BL-M07D1)

Not yet recruiting
  • Her2-positive/Low-expression Urinary and Digestive Tract Tumors
  • Beijing, Beijing, China
    Cancer Hospital, Chinese Academy of Medical Sciences
Sep 8, 2023

HER2-positive Solid Tumor, HER-2 Positive Cancer Trial (89Zr-trastuzumab)

Withdrawn
  • HER2-positive Solid Tumor
  • HER-2 Positive Cancer
  • (no location specified)
Dec 7, 2021

Bladder Cancer, Head and Neck Squamous Cell Carcinoma, Cancer of the Salivary Gland Trial in Houston (CAdVEC)

Recruiting
  • Bladder Cancer
  • +9 more
  • CAdVEC
  • Houston, Texas
    Baylor St. Luke's Medical Center
Feb 17, 2022

Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer Trial (BGB-43395, Fulvestrant, Letrozole)

Not yet recruiting
  • Advanced Solid Tumor
  • +8 more
  • (no location specified)
Nov 13, 2023

HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2-positive NSCLC Trial (XMT-2056)

Not yet recruiting
  • HER2-positive Breast Cancer
  • +4 more
  • (no location specified)
Aug 23, 2022

Solid Tumor Trial (HER2-E-CART cells)

Not yet recruiting
  • Solid Tumor
  • HER2-E-CART cells
  • (no location specified)
Feb 16, 2023

Tumors Trial in Germany, Switzerland, United Kingdom (MP0274)

Completed
  • Neoplasms
  • Frankfurt, Germany
  • +3 more
Jan 6, 2022

HER2-positive Advanced Solid Tumor Trial in Zigong (ZV0203)

Enrolling by invitation
  • HER2-positive Advanced Solid Tumor
  • Zigong, Shandong, China
    PKUCare Luzhong Hospital
Jun 14, 2022

Esophageal Tumors, Gastric Tumors Malignant, Breast Cancer Trial in Stockholm ([68Ga]Ga-ABY-025 PET, Biopsy and analysis of HER2

Recruiting
  • Esophageal Neoplasms
  • +3 more
  • [68Ga]Ga-ABY-025 PET
  • Biopsy and analysis of HER2 expression
  • Stockholm, Sweden
    Department of Radiation Physics and Nuclear Medicine, Karolinska
Nov 25, 2022

HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2-positive Bladder Cancer Trial in United States (PRS-343)

Completed
  • HER2-positive Breast Cancer
  • +3 more
  • Tucson, Arizona
  • +9 more
Jan 18, 2022

HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2-positive Metastatic Breast Cancer Trial in Germany, Spain,

Recruiting
  • HER2-positive Breast Cancer
  • +4 more
  • Essen, Germany
  • +5 more
Nov 15, 2022

Solid Tumors, Adult Trial in Dallas, Hangzhou (HF158K1 /Arm 2 mg/m², HF158K1 /Arm 6 mg/m², HF158K1 /Arm 15 mg/m²)

Not yet recruiting
  • Solid Tumors, Adult
  • HF158K1 /Arm 2 mg/m²
  • +5 more
  • Dallas, Texas
  • +2 more
May 6, 2023

HER2-positive Breast Cancer, HER-2 Protein Overexpression, HER-2 Gene Amplification Trial in San Antonio, Fairfax (ORM-5029)

Not yet recruiting
  • HER2-positive Breast Cancer
  • +3 more
  • San Antonio, Texas
  • +1 more
Aug 22, 2022

Metastatic Solid Tumor, Brain Metastases Trial in Houston (Trastuzumab emtansine, Tucatinib)

Not yet recruiting
  • Metastatic Solid Tumor
  • Brain Metastases
  • Houston, Texas
    M D Anderson Cancer Center
Dec 30, 2022

HER2-positive Breast Cancer, Metastatic Cancer, Metastatic Breast Cancer Trial in Chicago, Minneapolis (ALX148, Fam-Trastuzumab

Recruiting
  • HER2-positive Breast Cancer
  • +17 more
  • ALX148
  • Fam-Trastuzumab Deruxtecan-Nxki
  • Chicago, Illinois
  • +1 more
May 19, 2023

HER2-Positive Advanced Solid Tumors Trial (Zanidatamab)

Available
  • HER2-Positive Advanced Solid Tumors
  • (no location specified)
Feb 8, 2022

HER2-positive, Adenocarcinoma, Bile Duct Cancer Trial in United States (CT-0508)

Recruiting
  • HER2-positive
  • +30 more
  • CT-0508
  • Duarte, California
  • +4 more
Feb 1, 2022

HER2-Positive Solid Tumors Trial (Chort 1 of M802, Chort 2 of M802, Cohort 3 of M802)

Not yet recruiting
  • HER2-Positive Solid Tumors
  • Chort 1 of M802
  • +7 more
  • (no location specified)
Jul 28, 2021

HER2 Positive Solid Tumors Trial in Australia, Korea, Republic of, United States (SBT6050, pembrolizumab, Cemiplimab)

Active, not recruiting
  • HER2 Positive Solid Tumors
  • Boston, Massachusetts
  • +11 more
Jun 27, 2022